An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence.

NCT ID: NCT00138749

Last Updated: 2011-04-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

402 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-11-30

Study Completion Date

2006-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study designed to assess the efficacy, toleration and safety of SS-RBX for the treatment of stress urinary incontinence.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urinary Incontinence, Stress

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SS-RBX

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinically significant stress urinary incontinence

Exclusion Criteria

* History or evidence of any relevant confounding urological or neurological disease
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pfizer Inc

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Anchorage, Alaska, United States

Site Status

Pfizer Investigational Site

Sun City, Arizona, United States

Site Status

Pfizer Investigational Site

Tucson, Arizona, United States

Site Status

Pfizer Investigational Site

Tucson, Arizona, United States

Site Status

Pfizer Investigational Site

Little Rock, Arkansas, United States

Site Status

Pfizer Investigational Site

Atherton, California, United States

Site Status

Pfizer Investigational Site

Carmichael, California, United States

Site Status

Pfizer Investigational Site

Laguna Woods, California, United States

Site Status

Pfizer Investigational Site

Murrieta, California, United States

Site Status

Pfizer Investigational Site

Newport Beach, California, United States

Site Status

Pfizer Investigational Site

Sacramento, California, United States

Site Status

Pfizer Investigational Site

San Diego, California, United States

Site Status

Pfizer Investigational Site

Tarzana, California, United States

Site Status

Pfizer Investigational Site

Temecula, California, United States

Site Status

Pfizer Investigational Site

Torrance, California, United States

Site Status

Pfizer Investigational Site

Vista, California, United States

Site Status

Pfizer Investigational Site

Aurora, Colorado, United States

Site Status

Pfizer Investigational Site

Denver, Colorado, United States

Site Status

Pfizer Investigational Site

Denver, Colorado, United States

Site Status

Pfizer Investigational Site

Wheat Ridge, Colorado, United States

Site Status

Pfizer Investigational Site

New London, Connecticut, United States

Site Status

Pfizer Investigational Site

Waterbury, Connecticut, United States

Site Status

Pfizer Investigational Site

Aventura, Florida, United States

Site Status

Pfizer Investigational Site

New Port Richey, Florida, United States

Site Status

Pfizer Investigational Site

Panama City, Florida, United States

Site Status

Pfizer Investigational Site

Panama City, Florida, United States

Site Status

Pfizer Investigational Site

Pembroke Pines, Florida, United States

Site Status

Pfizer Investigational Site

Port Richey, Florida, United States

Site Status

Pfizer Investigational Site

West Palm Beach, Florida, United States

Site Status

Pfizer Investigational Site

Alpharetta, Georgia, United States

Site Status

Pfizer Investigational Site

Coeur d'Alene, Idaho, United States

Site Status

Pfizer Investigational Site

Arlington Heights, Illinois, United States

Site Status

Pfizer Investigational Site

Chicago, Illinois, United States

Site Status

Pfizer Investigational Site

Melrose Park, Illinois, United States

Site Status

Pfizer Investigational Site

Greenwood, Indiana, United States

Site Status

Pfizer Investigational Site

Indianapolis, Indiana, United States

Site Status

Pfizer Investigational Site

Des Moines, Iowa, United States

Site Status

Pfizer Investigational Site

Louisville, Kentucky, United States

Site Status

Pfizer Investigational Site

Shreveport, Louisiana, United States

Site Status

Pfizer Investigational Site

Greenbelt, Maryland, United States

Site Status

Pfizer Investigational Site

Watertown, Massachusetts, United States

Site Status

Pfizer Investigational Site

Jackson, Mississippi, United States

Site Status

Pfizer Investigational Site

Jackson, Mississippi, United States

Site Status

Pfizer Investigational Site

Liberty, Missouri, United States

Site Status

Pfizer Investigational Site

North Kansas City, Missouri, United States

Site Status

Pfizer Investigational Site

Omaha, Nebraska, United States

Site Status

Pfizer Investigational Site

Henderson, Nevada, United States

Site Status

Pfizer Investigational Site

Edison, New Jersey, United States

Site Status

Pfizer Investigational Site

West Orange, New Jersey, United States

Site Status

Pfizer Investigational Site

Albuquerque, New Mexico, United States

Site Status

Pfizer Investigational Site

Albany, New York, United States

Site Status

Pfizer Investigational Site

Garden City, New York, United States

Site Status

Pfizer Investigational Site

Garden City, New York, United States

Site Status

Pfizer Investigational Site

Mineola, New York, United States

Site Status

Pfizer Investigational Site

Poughkeepsie, New York, United States

Site Status

Pfizer Investigational Site

Burlington, North Carolina, United States

Site Status

Pfizer Investigational Site

Charlotte, North Carolina, United States

Site Status

Pfizer Investigational Site

Concord, North Carolina, United States

Site Status

Pfizer Investigational Site

Fayetteville, North Carolina, United States

Site Status

Pfizer Investigational Site

Winston-Salem, North Carolina, United States

Site Status

Pfizer Investigational Site

Cincinnati, Ohio, United States

Site Status

Pfizer Investigational Site

Bethany, Oklahoma, United States

Site Status

Pfizer Investigational Site

Eugene, Oregon, United States

Site Status

Pfizer Investigational Site

Eugene, Oregon, United States

Site Status

Pfizer Investigational Site

Medford, Oregon, United States

Site Status

Pfizer Investigational Site

Portland, Oregon, United States

Site Status

Pfizer Investigational Site

Colmar, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Lancaster, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Pittsburgh, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Sellersville, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Sewickley, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Providence, Rhode Island, United States

Site Status

Pfizer Investigational Site

Charleston, South Carolina, United States

Site Status

Pfizer Investigational Site

Columbia, South Carolina, United States

Site Status

Pfizer Investigational Site

Greer, South Carolina, United States

Site Status

Pfizer Investigational Site

Myrtle Beach, South Carolina, United States

Site Status

Pfizer Investigational Site

Knoxville, Tennessee, United States

Site Status

Pfizer Investigational Site

Knoxville, Tennessee, United States

Site Status

Pfizer Investigational Site

Corpus Christi, Texas, United States

Site Status

Pfizer Investigational Site

Corsicana, Texas, United States

Site Status

Pfizer Investigational Site

Houston, Texas, United States

Site Status

Pfizer Investigational Site

San Antonio, Texas, United States

Site Status

Pfizer Investigational Site

Salt Lake City, Utah, United States

Site Status

Pfizer Investigational Site

Sandy City, Utah, United States

Site Status

Pfizer Investigational Site

Sandy City, Utah, United States

Site Status

Pfizer Investigational Site

West Jordan, Utah, United States

Site Status

Pfizer Investigational Site

Virginia Beach, Virginia, United States

Site Status

Pfizer Investigational Site

Seattle, Washington, United States

Site Status

Pfizer Investigational Site

Surrey, British Columbia, Canada

Site Status

Pfizer Investigational Site

Victoria, British Columbia, Canada

Site Status

Pfizer Investigational Site

Kitchener, Ontario, Canada

Site Status

Pfizer Investigational Site

Oakville, Ontario, Canada

Site Status

Pfizer Investigational Site

Montreal, Quebec, Canada

Site Status

Pfizer Investigational Site

Pointe-Claire, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A6061023

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Fesoterodine Flexible Dose Study
NCT00536484 COMPLETED PHASE3